A popular Knoxville restaurant reopens 14 months after kitchen fire became an 'inferno'
The Burlington branch of Buddy's Bar-B-Q has reopened more than a year after it nearly burnt to the ground.
The 3700 Magnolia Ave. restaurant first opened in 1983 as just the third Buddy's Bar-B-Q, a third-generation restaurant brand with 19 locations across East Tennessee. Buddy's CEO Mark Lemoncelli said the community response to the returning restaurant has been as if a brand-new location were opening.
In February 2024, the Buddy's in Burlington suffered a kitchen fire that engulfed the building in flames.
"The manager had just left the building, and it basically turned into a giant inferno," Lemoncelli said. "It just took on a life of its own."
This location didn't look like the other Buddy's. It had a flatter, square-like roof and was missing the recognizable red top. The building was minutes away from completely collapsing during the fire, Lemoncelli said.
Buddy's Bar-B-Q rebuilt its Magnolia Avenue restaurant in the Burlington neighborhood after a 2024 fire.
Once the fire was put out, he knew the restaurant would need to be mostly redone. The location was closed for 14 months, Lemoncelli said, since "they had to go down to four walls and rebuild."
This Buddy's now has the iconic red roof, along with interior renovations and kitchen upgrades. More than 60% of the staff that worked at Buddy's before the fire returned after the restaurant reopened April 28, Lemoncelli said.
"They know a lot of the community that comes in," he said. "It's been good to see. It's been encouraging."
Buddy's CEO also reopens Jason's Deli on the Strip
Lemoncelli also is the franchise owner of Jason's Deli at 2106 Cumberland Ave., which returned to the Strip in April after being closed more than four years.
The nationwide sandwich chain had to close its campus-area restaurant in December 2020 after developers began buying up real estate on Cumberland Avenue to make way for more private housing for University of Tennessee at Knoxville students.
Jason's Deli has reopened on the same block but is now inside the new Union Knoxville building, a student housing project backed by global real estate firm Greystar. In 2021, the strip mall that housed Jason's Deli, Subway and Domino's in the 2100 block of Cumberland Avenue was demolished to make way for the apartments.
Joanna Hayes is the restaurant and retail reporter. Email: joanna.hayes@knoxnews.com. | Sign up for the free Eat65 newsletter
Support strong local journalism by subscribing at subscribe.knoxnews.com.
This article originally appeared on Knoxville News Sentinel: Knoxville restaurant Buddy's Bar-B-Q reopens after Magnolia Avenue fire
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera's closing trading price on June 3, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, 2025, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit For more information, please contact: Investor Contact:Joyce AllaireLifeSci Advisors212-915-2569jallaire@ Media Contact:Debra CharlesworthVera Therapeutics415-854-8051corporatecommunications@
Time Business News
4 hours ago
- Time Business News
A Perfect Wedding Day in Dublin with Compton Chauffeurs
Emma and Jack were all set to tie the knot in the heart of Dublin. Everything was ready – the venue, the dress, the guests – but one thing was left. They wanted something special and smooth for their ride. After some research, they chose the Compton Chauffeurs service in Dublin. Emma called the team a few weeks before the big day. The process was simple and professional. She shared her wedding details, and the staff helped her pick the perfect car. They chose a Mercedes-Benz E-Class for the bride and a B-Class for family members. Everything was booked and confirmed in minutes. The chauffeur arrived on time. The car was shiny, clean, and decorated exactly as the couple wanted. The driver, wearing a suit, welcomed Emma and her father warmly. The ride was smooth and peaceful. Emma reached the venue feeling calm and relaxed. After saying 'I do,' it was time for some amazing pictures. The Mercedes made a perfect background for wedding photos in Phoenix Park, Dublin. The couple loved how professional the chauffeur was. He waited patiently, helped with the door, and even suggested good spots for pictures. Later, Emma and Jack were driven to the reception hall. The mood was joyful, and the music played softly in the background. It felt like a movie scene. They reached safely and on time. Everything was perfect. 'Compton Chauffeurs made our day even more special. We felt like VIPs from start to finish!' – Emma & Jack Luxury cars like Mercedes E-Class and B-Class like Mercedes E-Class and B-Class Professional drivers in suits in suits Always on time and reliable Perfect for photos and memories Service available across Ireland 📞 Phone: +353-87 239 9394 Website: 📧 Email: john@ 📍 Address: Ireland 🕒 Hours: 24/7 Let Compton Chauffeurs be a part of your love story. TIME BUSINESS NEWS
Business Wire
10 hours ago
- Business Wire
IonQ Speeds Quantum-Accelerated Drug Development Application With AstraZeneca, AWS, and NVIDIA
COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, announced results of a collaborative research program between IonQ, AstraZeneca, Amazon Web Services (AWS), and NVIDIA to develop and demonstrate a quantum-accelerated computational chemistry workflow which has the potential to power world-changing innovation in healthcare, life sciences, chemistry, and more. The results of the collaboration will be showcased at the ISC High Performance conference, which takes place on June 10-13, 2025, in Hamburg, Germany. The IonQ-designed workflow provides an end-to-end example of a hybrid quantum-classical workflow that helps provide solutions to complex pharmaceutical development challenges, and has the potential to improve speed and efficiency within the drug development process. Developing new drugs can take ten or more years and cost billions of dollars, so advancements that streamline early-stage research and reduce computational bottlenecks can unlock significant strategic and commercial value. This demonstration focused on a critical step in a Suzuki-Miyaura reaction – a class of chemical transformations used for the synthesis of small molecule drugs. By integrating IonQ's Forte quantum processing unit (QPU) with the NVIDIA CUDA-Q platform through Amazon Braket and AWS ParallelCluster services, the team achieved more than 20 times improvement in end-to-end time-to-solution compared to previous implementations. The technique maintained accuracy while reducing the overall expected runtime from months to days. 'This demonstration with AstraZeneca represents a meaningful step toward practical quantum computing applications in chemistry and materials science and showcases how IonQ's enterprise-grade quantum computers are uniquely suited to meet the challenge,' said Niccolo de Masi, CEO of IonQ. 'The ability to model catalytic reactions with speed and accuracy isn't just a scientific achievement, it's a preview of how hybrid computing with quantum acceleration will provide revolutionary capabilities to the industry.' 'This collaboration marks an important step towards accurately modeling activation barriers for catalyzed reactions relevant to route optimizing in drug development. We look forward to further advancements in the area,' said Anders Broo, Executive Director, Pharmaceutical Science, R&D, AstraZeneca. 'Future quantum computers are not going to replace traditional compute, but instead accelerate specific, computationally intensive processing steps as part of HPC processing pipelines,' said Eric Kessler, GM of Amazon Braket at AWS. 'By combining quantum computers on Amazon Braket with scalable GPU resources on AWS, we're supporting AstraZeneca to envision how future quantum computers will be used to accelerate research in computational chemistry.' 'Bringing together state-of-the-art quantum and GPU computing in hybrid workflows is the path to realizing quantum's potential,' said Tim Costa, Senior Director of Quantum and CUDA-X at NVIDIA. 'This work represents a meaningful step towards applying quantum accelerated supercomputing to important use cases.' IonQ and its partners demonstrated a large-scale, end-to-end simulation of a Suzuki-Miyaura reaction, which is the most complex chemical simulation run on IonQ hardware to date. The hybrid quantum-classical workflow – orchestrated via CUDA-Q on Amazon Braket, accelerated with NVIDIA H200 GPUs through AWS ParallelCluster – delivered more than a 20x speedup in time-to-solution compared to prior benchmarks. This advancement highlights the scalability of IonQ's quantum systems and their practical potential in pharmaceutical R&D. These results show how hybrid quantum computing can overcome computational limits in high-accuracy molecular modeling and enables the analysis of more complex chemical systems. It builds on recent IonQ demonstrations of practical applications where hybrid quantum-classical approaches outperformed purely classical methods. For more information on this research, please visit the IonQ booth #A25 at the ISC High Performance conference in Hamburg, Germany on June 10-13, 2025 or read the full research paper at our technical blog post. About IonQ IonQ, Inc. is a leading commercial quantum computing and networking company, delivering high-performance systems aimed at solving the world's largest and most complex commercial and research use cases. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'accessible,' 'aimed,' 'available,' 'can,' 'cutting-edge,' 'delivering,' 'enables,' 'growth,' 'innovative,' 'impactful,' 'latest,' 'leader,' 'leading,' 'making,' 'potential,' 'provide,' 'solving,' 'toward,' 'will,' and other similar expressions are intended to identify forward-looking statements. These statements include those related to the IonQ's quantum computing capabilities and plans; IonQ's technology driving commercial quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the relevance and utility of quantum algorithms and applications run on IonQ's quantum computers; the necessity, effectiveness, and future impacts of IonQ's offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, significance, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings; and IonQ's ability to deliver higher speed and fidelity gates with fewer errors, enhance information transfer and network accuracy, or reduce noise and errors. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's most recent periodic financial report (10-Q or 10-K) filed by IonQ with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
